Market closed·Syncing…
SMEMarket closed · Close · 19 Nov

Sotac Pharmaceuticals Limited SOTACshare price and chart

Sotac Pharmaceuticals closed at ₹129.00 on 19 November 2026, up 4.96% on the day. The 52-week range is ₹86.00 to ₹139.65.

₹129.00The price one share last traded at, in rupees.+4.96% · ₹6.10
52-wk low ₹8680% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹140

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on SOTAC

Real prices, every charge counted. Pick one or write your own.
What Sotac Pharmaceuticals Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Sotac Pharmaceuticals researches and develops pharmaceutical molecules and formulation technologies, and through its majority-owned subsidiary SOTAC Lifescience makes nutraceutical and food products under contract manufacturing.

1
1Sector

Pharmaceuticals & Biotechnology

2
2What it sells

Pharmaceutical formulations, nutraceuticals

3
3Who buys it

Pharma and nutraceutical brands

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 19 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
68.6Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
100%Near average
today 100%20d avg 98%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+20.0%1 monthHow much the share price has changed over the period.+27.7%3 monthsHow much the share price has changed over the period.+21.1%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.54.5%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹143 Cr19 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.16.5xlast 4 quarters, to Sept 2026Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.2.22xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.13.3%full year FY26Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.16%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.64xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.10.3%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Pharmaceuticals · 141 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.16.5vs 32.92 median
Cheapest: WALPAR 7.92Priciest: COHANCE 510.5
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.6.32%vs 10.23% median
Lowest: MEDIORG -86.72%Highest: SHUKRAPHAR 38.89%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.106.83%vs 20.87% median
Lowest: NECLIFE -99.78%Highest: SHUKRAPHAR 652.15%

Dividend historyCash the company has paid per share, year by year.

₹160 / year
Paid 2 of 2 yrs
on ₹1 lakh at today's price · 0.16% yield · ₹0.2/share
What each year paid, on ₹1 lakh
78
155
25
26*
* 2026 so far - more may still be declared this year

2026 has paid ₹0.20 per share, about ₹155 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+1.6%a year, over 3 years
1 yr
+3.2%
3 yr
+1.6%

Held for 3 years this compounded at +1.6% a year. The last twelve months were up +3.2%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
72.85%promoter holding, as of 2026-09-30+0.0 pts since 2023
Promoter share since listing
2023-0472.85% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
72.8%
16.5%
Promoter72.8%Foreign (FII)16.5%Public & others10.7%
Who is buying, who is leavingSep 25 to Sep 26
Promoter72.8%steady
Foreign (FII)16.5%+0.3 pts
Domestic (DII)
-

Each line is that holder's share of all shares over the last 3 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Outcome of Board Meeting13-Nov-2026

Sotac Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

General Updates05-Nov-2026

Sotac Pharmaceuticals Limited has informed the Exchange about General Updates regarding Clarification in price movement.

Price movement03-Nov-2026

Significant movement in price has been observed in Sotac Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

Amendment to AOA/MOA03-Nov-2026

Sotac Pharmaceuticals Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.

Shareholders meeting02-Nov-2026

Sotac Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Extraordinary General Meeting held on October 31, 2026. Further, the company has informed the Exchange regarding voting results.

Shareholders meeting31-Oct-2026

Sotac Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on October 31, 2026

Certificate under SEBI (Depositories and Participants) Regulations, 201812-Oct-2026

Sotac Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30,2026.

Copy of Newspaper Publication12-Oct-2026

Sotac Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

Shareholders meeting08-Oct-2026

Sotac Pharmaceuticals Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on October 31, 2026

Outcome of Board Meeting08-Oct-2026

Sotac Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on October 08, 2026.

Shareholders meeting01-Oct-2026

Sotac Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting results.

Shareholders meeting30-Sep-2026

Sotac Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026

Trading Window30-Sep-2026

Sotac Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Copy of Newspaper Publication08-Sep-2026

Sotac Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

General Updates08-Sep-2026

Sotac Pharmaceuticals Limited has informed the Exchange about Regulation 36(1)(b) of the SEBI Listing Regulations regarding letter to shareholders

Backtest idea · SOTACMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on SOTAC
Backtest idea · SOTACLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on SOTAC
Backtest idea · SOTACSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on SOTAC
Your own ideaWrite a rule for SOTAC in plain English“Buy SOTAC when …”
Start writing
Buy the dip on SOTACBuy when RSI(14) drops below 30
52-week high breakout on SOTACBuy when closes at a 52-week high
Golden cross on SOTACBuy when 50-day EMA crosses above 200-day
Stochastic oversold on SOTACBuy when stochastic %K drops below 20
Pullback in an uptrend on SOTACBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹143 cr
Larger than 16% of 141 peers
sector middle ₹2,738 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
16.5x
Lower than 88% of 118 peers
sector middle 32.9x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
2.2x
Lower than 73% of 125 peers
sector middle 3.6x
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
13.3%
Lower than 56% of 124 peers
sector middle 15.0%
FY25 14.1%FY26 13.3%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.64
Higher than 88% of 125 peers
sector middle 0.19
FY25 0.82FY26 0.64
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.2%
Higher than 55% of 141 peers
sector middle 0.1%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+106.8%
Higher than 93% of 130 peers
sector middle +20.9%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash fell by ₹0 Cr, after ₹6 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹17 Cr
Investing-₹7 Cr
Lenders and shareholders-₹10 Cr
Net change in cash-₹0 Cr

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY25FY26
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.14.1%13.3%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.82x0.64x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · SOTACStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on SOTAC
Backtest idea · SOTACPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on SOTAC
Backtest idea · SOTACBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on SOTAC
Backtest idea · SOTAC52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on SOTAC
Backtest idea · SOTACGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on SOTAC
MACD momentum on SOTACBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on SOTACBuy when closes below the lower Bollinger band
Supertrend rider on SOTACBuy when supertrend turns up
Buy the dip on SOTACBuy when RSI(14) drops below 30
52-week high breakout on SOTACBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Pharmaceuticals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.56 L cr41.6x5.1x14.7%19.1%0.0317.8%+11.9%0.84%
DIVISLAB
Divi's Laboratories Limited
2.97 L cr88.2x16.5x16.2%21.5%0.0027.6%+35.4%0.27%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.75 L cr77.9x9.6x17.0%15.2%0.7612.1%+50.8%0.82%
LAURUSLABS
Laurus Labs Limited
1.25 L cr92.9x20.6x17.7%17.9%0.4017.0%+33.4%0.10%
ZYDUSLIFE
Zydus Lifesciences Limited
1.20 L cr28.9x4.3x18.3%19.9%0.4414.1%+29.2%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.17 L cr41.7x3.0x11.5%13.9%0.158.3%-1.5%0.57%
CIPLA
Cipla Limited
1.15 L cr39.5x3.2x11.7%16.0%0.0110.1%-2.4%0.92%
MANKIND
Mankind Pharma Limited
1.09 L cr48.4x6.2x12.4%12.9%0.3014.7%+17.3%0.00%
AUROPHARMA
Aurobindo Pharma Limited
1.04 L cr26.2x2.6x9.9%12.8%0.2110.8%+23.9%0.39%
LUPIN
Lupin Limited
91,403 cr17.6x3.8x26.9%28.8%0.2317.0%+11.1%0.90%
GLENMARK
Glenmark Pharmaceuticals Limited
73,618 cr50.7x6.6x14.1%20.4%0.089.2%-31.3%0.10%
ALKEM
Alkem Laboratories Limited
61,516 cr29.8x4.1x17.6%20.6%0.1213.4%+13.8%1.03%
BIOCON
Biocon Limited
59,264 cr216.5x1.7x1.1%3.0%0.411.9%+2.2%0.14%
ABBOTINDIA
Abbott India Limited
54,600 cr33.0x----23.0%+11.0%2.55%
GLAND
Gland Pharma Limited
54,336 cr43.9x5.1x10.5%15.0%0.0217.5%+23.3%0.61%
IPCALAB
IPCA Laboratories Limited
47,189 cr33.6x5.4x13.2%16.6%0.0614.2%+13.8%0.32%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
45,967 cr40.6x24.4x48.9%66.5%0.0027.6%+20.8%2.10%
EMCURE
Emcure Pharmaceuticals Limited
44,481 cr40.7x8.3x19.6%24.8%0.2710.7%+24.3%0.15%
AJANTPHARM
Ajanta Pharma Limited
40,865 cr32.4x8.4x25.4%32.7%0.0220.3%+32.5%0.98%
SAILIFE
Sai Life Sciences Limited
37,985 cr100.5x14.1x15.1%20.9%0.1715.9%+22.5%0.00%
WOCKPHARMA
Wockhardt Limited
35,537 cr86.7x6.9x4.0%6.5%0.3910.8%+23.9%0.00%
ACUTAAS
Acutaas Chemicals Limited
32,561 cr74.1x17.5x23.5%31.7%0.0027.5%+42.7%0.06%
PPLPHARMA
Piramal Pharma Limited
31,906 cr-3.9x-4.0%0.8%0.69-2.1%+28.1%0.00%
RUBICON
Rubicon Research Limited
28,510 cr87.3x20.1x19.1%23.4%0.2815.5%+39.9%0.09%
NEULANDLAB
Neuland Laboratories Limited
27,074 cr59.8x13.3x21.4%27.5%0.1719.6%-12.6%0.16%
APLLTD
Alembic Pharmaceuticals Limited
20,631 cr24.4x3.5x12.4%11.7%0.259.9%+36.3%1.14%
GRANULES
Granules India Limited
19,853 cr27.7x3.0x13.5%15.7%0.0912.1%+20.3%0.22%
ERIS
Eris Lifesciences Limited
18,418 cr25.8x4.4x18.1%13.9%0.5821.6%+12.6%0.54%
ONESOURCE
Onesource Specialty Pharma Limited
18,381 cr-3.1x-1.3%0.4%0.25-0.1%+37.4%0.00%
ALIVUS
Alivus Life Sciences Limited
17,801 cr26.6x4.9x18.4%24.6%0.0024.9%+16.0%0.34%
SHILPAMED
Shilpa Medicare Limited
17,616 cr52.7x6.4x9.8%11.4%0.2418.1%+43.0%0.07%
PFIZER
Pfizer Limited
17,614 cr20.5x4.0x17.2%23.4%0.0032.4%+13.2%1.95%
COHANCE
Cohance Lifesciences Limited
17,578 cr510.5x4.5x5.1%8.0%0.06-0.3%-14.2%0.00%
NATCOPHARM
Natco Pharma Limited
16,124 cr17.8x1.6x16.9%17.1%0.1126.9%-29.0%0.70%
CAPLIPOINT
Caplin Point Laboratories Limited
15,845 cr23.0x4.1x19.9%24.7%0.0029.4%+17.9%0.38%
ASTRAZEN
AstraZeneca Pharma India Limited
15,283 cr86.0x17.4x22.8%31.2%0.006.8%+30.4%0.59%
JUBLPHARMA
Jubilant Pharmova Limited
14,865 cr56.2x2.1x6.0%8.7%0.542.9%+20.5%0.54%
CORONA
CORONA Remedies Limited
13,680 cr66.1x17.0x24.8%27.8%0.1213.3%+22.2%0.45%
MARKSANS
Marksans Pharma Limited
13,556 cr24.2x4.1x25.4%35.1%0.0116.7%+30.5%0.30%
SOTAC
Sotac Pharmaceuticals Limited
143 cr16.5x2.2x-13.3%0.646.3%+106.8%0.16%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-3.9
-6.2
-1.6
+7.1
-5.1
-5.4
-12.4
-2.1
·
·
+15.5
·
-15.5%
9m
2025
-2.1
-3.7
+15.3
+5.2
+0.8
+15.2
-13.8
+10.0
-21.4
+20.1
+6.7
-11.1
+12.6%
2024
+6.4
+23.5
-21.9
+1.6
-6.5
+21.3
+6.6
+4.3
-14.8
-5.3
-8.0
-5.0
-7.4%
2023
·
·
·
·
+19.1
-11.0
-3.6
+6.8
-1.2
-7.3
+8.7
-5.6
+2.6%
8m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2026-03-13SAMBHAVNATH INVESTMENTS AND FINANCES PRIVATE LIMITED · bulkSELL1,89,600₹110.55₹2.10 Cr
2026-03-13ADITYA ENTERPRISE · bulkBUY1,70,400₹110.55₹1.88 Cr
2025-03-20GOENKA BUSINESS & FINANCE LIMITED · bulkSELL1,83,600₹120.00₹2.20 Cr
2025-03-20CRAFT EMERGING MARKET FUND PCC- ELITE CAPITAL FUND · bulkBUY1,83,600₹120.00₹2.20 Cr
2025-03-10GOENKA BUSINESS & FINANCE LIMITED · bulkSELL1,81,200₹93.58₹1.70 Cr
2025-03-10CRAFT EMERGING MARKET FUND PCC- ELITE CAPITAL FUND · bulkBUY1,81,200₹93.58₹1.70 Cr
2025-03-04SAMBHAVNATH INVESTMENTS AND FINANCES PRIVATE LIMITED · bulkSELL1,53,600₹102.80₹1.58 Cr
2025-03-04CRAFT EMERGING MARKET FUND PCC- ELITE CAPITAL FUND · bulkBUY1,53,600₹102.80₹1.58 Cr

Read enough? Test SOTAC. “Buy SOTAC when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free